Home Newsfeeds Needham Upgrades NeoGenomics to Buy, Announces $15 Price Target

Needham Upgrades NeoGenomics to Buy, Announces $15 Price Target

Needham analyst Mike Matson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $15 price target.

byBenzinga Newsdesk

February 1, 2023

1 minute read

Needham analyst Mike Matson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $15 price target.

From $3,000 To $250 Million: Friends’ T-Shirt Venture Becomes A Massive Success Story

By Bibhu Pattnaik

August 14, 1:39 PM

Ryan Bartlett and his friends Nick Ventura and Matthew Winnick combined their resources in 2019 with a modest $3,000 investment to establish the men's apparel brand True Classic.

NKE

Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $3

By Benzinga Newsdesk

March 20, 4:33 AM

Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $4 to $3.

AVAH

Fear & Greed Index Moves To ‘Neutral’ Zone As US Stocks Record Gains

By Lisa Levin

April 3, 3:02 AM

The CNN Money Fear and Greed index moved to the "Neutral" zone on Friday. US stocks closed higher on Friday, also recording gains for the quarter after the Federal Reserve’s preferred gauge of inflation showed a cooler-than-expected rise in prices.

SAIC